Emerging Treatment Options for BRCA-Mutated Breast Cancer

Emerging Treatment Options for BRCA-Mutated Breast Cancer

Episodes

Specialty:

All

Year:

All

EP. 1: Emerging Options for BRCA-Mutated Breast Cancer Treatment

March 30th 2018

EP. 2: Implications for Germline BRCA Testing in Breast Cancer

March 30th 2018

EP. 3: Germline BRCA1/2: A New Subset of Breast Cancer

March 30th 2018

EP. 4: Chemotherapy in gBRCA1/2+ Metastatic Breast Cancer

March 30th 2018

EP. 5: Chemotherapy in Early-Stage gBRCA1/2+ Breast Cancer

March 30th 2018

EP. 6: Takeaways From the OlympiAD Trial

March 30th 2018

EP. 7: Olaparib: Predicting Response in Breast Cancer

March 30th 2018

EP. 8: Using Olaparib in gBRCA1/2+ Breast Cancer

March 30th 2018

EP. 9: Additional PARPs Under Investigation for Breast Cancer

March 30th 2018

EP. 10: PARP Inhibitors and Platinum Sensitivity or Resistance

March 30th 2018

EP. 11: Distinguishing Between PARP Inhibitors in Breast Cancer

March 30th 2018

EP. 12: PARP Inhibitors in Other Subtypes of Breast Cancer

March 30th 2018

EP. 13: Testing for Germline BRCA Mutations in the Future

March 30th 2018

EP. 14: Final Insight: PARPs and gBRCA in Breast Cancer

March 30th 2018

Trending on OncLive

Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC

Dr Voorhees on Eligibility Criteria for the CERVINO Trial in Multiple Myeloma

Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma

FDA Approves Belzutifan Plus Lenvatinib for Advanced ccRCC

Etentamig Improves Response and PFS vs Standard Therapies in Triple-Class Exposed Relapsed/Refractory Myeloma